Sign In
Buy VBIV
$0.0653
+0 (+0%)
At Close: Nov 15, 2024
VBI Vaccines' Three-Antigen HBV Vaccine Candidate Trial Data Published In Lancet Infectious Diseases
10:15am, Wednesday, 12'th May 2021
VBI Vaccines Inc (NASDAQ: VBIV) has announced that results from Phase 3 PROTECT trial of VBI's prophylactic 3-antigen hepatitis B (HBV) vaccine candidate in adults were published in The Lancet Inf
VBI Vaccines: Reloading My Position Ahead Of Transformative Catalysts
02:44pm, Wednesday, 28'th Apr 2021
VBI Vaccines has several potent catalysts on the docket that could have a substantial impact on the company's fundamental outlook.
Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study
08:50am, Wednesday, 21'st Apr 2021
Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in c
VBI Vaccines to Present at Oppenheimer 31st Annual Healthcare Conference
08:00am, Monday, 15'th Mar 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announ
8 Biotech Penny Stocks for Investors to Watch
11:54am, Wednesday, 10'th Mar 2021
Low-priced biotechs have sold off recently, but there could still be potential in these picks. Here are eight penny stocks to consider.
CEPI, VBI Vaccines Collaborate To Develop COVID-19 Vaccine Candidates Against Variants
09:26am, Wednesday, 10'th Mar 2021
The Coalition for Epidemic Preparedness Innovations (CEPI) and VBI Vaccines Inc (NASDAQ: VBIV) entered into a partnership for the development of VBI's enveloped virus-like particle (eVLP) vaccine
VBI Vaccines (VBIV) Up on Monovalent COVID-19 Vaccine Study
09:06am, Wednesday, 10'th Mar 2021
VBI Vaccines (VBIV) is developing a monovalent and trivalent COVID-19 vaccines in separate phase I/II studies.
CEPI and VBI Vaccines Collaborate to Advance Vaccine Candidates Against COVID-19 Variants
07:00am, Wednesday, 10'th Mar 2021
OSLO, Norway & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--CEPI, the Coalition for Epidemic Preparedness Innovations, and VBI Vaccines Inc. (Nasdaq: VBIV), today announced a partnership to develop VB
VBI Vaccines, Inc. (VBIV) Reports Q4 Loss, Lags Revenue Estimates
10:37am, Tuesday, 02'nd Mar 2021
VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 0.00% and -62.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
VBI Vaccines Announces U.S. FDA Acceptance of BLA Filing for VBI's 3-Antigen Prophylactic Hepatitis B Vaccine
08:00am, Tuesday, 02'nd Feb 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vacc
10 Short Squeeze Candidates Under $10
08:36am, Saturday, 30'th Jan 2021
The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's
VBI Vaccines (VBIV) Provides Updates on COVID-19 Vaccine
03:03pm, Friday, 22'nd Jan 2021
VBI Vaccines (VBIV) plans to begin a phase I/II study of monovalent vaccine candidate, VBI-2902, in the first quarter of 2021.
Week 3 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge
05:43am, Sunday, 17'th Jan 2021
Week 3 MDA Breakout Stocks - January 2021: Short-Term Picks To Give You An Edge
Why Novartis, BioVie, Esperion And VBI Are Moving Today
11:47am, Friday, 15'th Jan 2021
Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Holdings i
Why VBI Vaccines Stock Is Vaulting Higher Today
11:28am, Friday, 15'th Jan 2021
The company reported good news from a study of its hepatitis B vaccine.
